Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
about
Updates on the risk factors for latent tuberculosis reactivation and their managementsA Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary TuberculosisEfficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analysesThree months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected personsPredictors of Latent Tuberculosis Infection Treatment After Introduction of a New Regimen: A Retrospective Cohort Study at an Inner City Clinic.Managing tuberculosis infection in children in the USA: an update.Rifapentine for the treatment of latent tuberculosis.Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?Tuberculosis contact investigation in an intermediate burden setting: implications from a large tuberculosis contact cohort in Taiwan.Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial.Treatment of Latent Tuberculosis Infection and Its Clinical Efficacy.A shorter treatment regimen for latent tuberculosis infection holds promise for at-risk Canadians.Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis InfectionIsoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysis
P2860
Q28073158-FE95D591-70EB-4228-AF62-7FB0BDC6F9F8Q36012300-26DDE5F9-549E-46E5-86AA-C8C66B10DDD9Q36343641-056D2BF0-E284-4107-8EAF-EA519184D2D9Q36986755-759924A6-437F-44C1-9785-FAEDA36B9BBDQ37343487-1000FFB9-0826-406E-AD3E-DD401F05FBFDQ38831038-A4DB8F04-3011-438D-88FE-F679A213FE5CQ38933165-DBC1FCD7-7608-43E4-8FB7-07A0D42C5F36Q40095703-F0ADD1D4-B8F0-4D78-AE2B-224996FAF6F5Q42357130-DE89B6DC-2382-4262-957B-904B5AEB6740Q47715774-625F97FA-1133-431E-B745-7A32E78A2D7EQ49521299-B5E84208-0765-411A-AAEB-9458997AA528Q54207981-7ECE007D-B08D-48EB-AD82-90A62A094864Q56067172-453210B5-9E25-452D-A54F-7F08AEFE49B3Q57568082-E3AA3454-1119-4113-B70A-186C968BBE44
P2860
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Flu-like and Other Systemic Dr ...... he PREVENT Tuberculosis Study.
@ast
Flu-like and Other Systemic Dr ...... he PREVENT Tuberculosis Study.
@en
type
label
Flu-like and Other Systemic Dr ...... he PREVENT Tuberculosis Study.
@ast
Flu-like and Other Systemic Dr ...... he PREVENT Tuberculosis Study.
@en
prefLabel
Flu-like and Other Systemic Dr ...... he PREVENT Tuberculosis Study.
@ast
Flu-like and Other Systemic Dr ...... he PREVENT Tuberculosis Study.
@en
P2093
P2860
P356
P1476
Flu-like and Other Systemic Dr ...... he PREVENT Tuberculosis Study.
@en
P2093
Andrey S Borisov
Christine Ho
Elizabeth Phillips
Gillian Shepherd
Margarita Elsa Villarino
Newton Franklin Adkinson
Ruth N Moro
Stephen Weis
Timothy R Sterling
Tuberculosis Trials Consortium
P2860
P304
P356
10.1093/CID/CIV323
P407
P577
2015-04-22T00:00:00Z